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Numerous factors interfere with the ability to achieve optimal pharmacokinetic and pharmacodynamic targets and
this has been associated with greater mortality and lower cure rates. The recent study by Zoller and colleagues
examining linezolid levels in critically ill patients emphasises this point. Their study is unique in the description of
the intra-patient and inter-patient variability that occurs and in the degree to which therapy is inadequate; 63%
of patients had insufficient levels and only 17% maintained optimal trough values (between 2 and 10 mg/l) throughout
the 4 study days. Precisely why this result occurred is uncertain because albumin levels, free linezolid pharmacokinetics
and the presence of augmented renal clearance were not recorded in the current study. The extent of this variability
makes the case for therapeutic drug monitoring since an area under the inhibitory curve greater than 80 to 120 and
the time above the minimum inhibitory concentration over the entire dosing interval strongly correlate with linezolid
treatment efficacy. Accordingly, therapeutic drug monitoring where available or, if not available, alternative approaches
to drug delivery such as continuous infusion or a dose increase – but particularly the former – may be the answer.Antibiotic dosing of critically ill patients is notoriously
difficult because multiple factors influence achievement of
pharmacokinetic and pharmacodynamic targets. Linezolid
(LZD) is no exception to this and strategies need to
be developed to ensure therapeutic adequacy.
The study by Zoller and colleagues in a previous issue
of Critical Care [1], who examined LZD levels in 30
critically ill patients, highlights this issue. Whilst therapeutic
drug monitoring (TDM) has traditionally been used to
minimise toxic effects, the study results support emerging
data that TDM should also be used to optimise dosing in
critically ill patients.
Numerous factors such as obesity, volume of distribution,
albumin levels, fluid losses and whether the drug is
hydrophobic or hydrophilic interfere with the ability
to achieve optimal pharmacokinetic and pharmacodynamic
targets and subsequent bacteriological and clinical success.
The free fraction is responsible for efficacy and toxicity but
is also available for clearance. In addition, the phenomenon
of augmented renal clearance has been associated with* Correspondence: Guy.richards@wits.ac.za
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creatinine clearance ≥150 ml/minute [2].
Whereas previous studies have investigated the
pharmacokinetic/pharmacodynamic parameters of LZD and
have described the difficulties associated with predicting
serum and tissue levels, the study by Zoller and colleagues
is unique primarily in the number of evaluations that were
performed and in the description of intra-patient and
inter-patient variability. The area under the concentration–
time curve for a drug is the basis on which the area under
the inhibitory curve (AUIC; the best pharmacodynamic
marker of efficacy for LZD) is calculated, and the trough
concentration is the concentration from which the time
above the minimum inhibitory concentration (T >MIC) is
calculated using the breakpoints of common Gram-positive
pathogens. Both of these parameters showed marked
variability in this study and, using the AUIC as a predictor
of adequacy of therapy, 63% of patients had insufficient
levels. Similarly, only 17% of patients maintained optimal
trough concentration values (between 2 and 10 mg/l)
throughout the 4 study days. Precisely why this result
occurred is uncertain.
In a LZD pharmacokinetics study, Lovering and col-
leagues demonstrated that although the volume of dis-
tribution and renal clearance were similar between healthy
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in a lower area under the concentration–time curve,
possibly due to loss of drug in burn exudate and thereafter
due to changes in basal metabolism [3]. Although this
situation was not the case here, nonrenal clearance might
have played a role. LZD is moderately protein bound
(±30%), so the impact of hypoalbuminaemia on target
attainment would be expected to be less than that of
highly protein-bound drugs. Wong and colleagues,
however, recently demonstrated variabilities in both
unbound and total concentrations that were significant for
all β-lactam antibiotics whether or not they were highly
protein bound [4]. In addition, in a recent multicentre
study 16% of 248 critically ill patients had T >MIC for free
β-lactam levels <50% and a positive clinical outcome was
associated with increasing the T >MIC to 50% (odds ratio,
1.02) and to 100% (odds ratio, 1.56) (P < 0.03) [5]. In the
current study, albumin levels, free LZD pharmacokinetics
and augmented renal clearance were not recorded.
The considerable and unpredictable inter-patient and
intra-patient variability recorded by Zoller and colleagues
certainly makes the case for TDM, as AUIC >80 to 120 and
T >MIC over the entire dosing interval strongly correlate
with LZD treatment efficacy [6]; unfortunately, TDM is not
yet generally available. Until it does become available, we
need to develop more generally applicable alternative
approaches to drug delivery. One of these approaches
might be continuous infusion, which reliably increases
levels above the breakpoint of 2 mg/l and avoids wide
swings in peak and trough levels [7]. In support of this
hypothesis, Boselli and colleagues demonstrated that a
loading dose followed by continuous infusion led to
concentrations twice that of a LZD minimum inhibitory
concentration of 4 mg/l in serum and epithelial lining
fluid for 100% of the time in critically ill patients with
ventilator-associated pneumonia [8]. Clearly, a lot more
work is necessary to confirm that this is the situation in
critically ill patients despite the alterations in physiological
parameters that occur. Alternatively, could increasing
the dose be the answer? Infusion of 1,800 mg/day
LZD should reliably increase levels into the thera-
peutic range but would also increase toxicity [9]. In
the current study, toxic levels occurred in 7% of patients
utilising the recommended dose, with no factors predictive
of risk other than a trend for higher levels with an elevated
creatinine level.
In conclusion, optimising the dose and method of
administration of LZD is essential. Whereas further
studies of both approaches described above are necessary
before firm recommendations can be made, it seems
reasonable to utilise TDM where available, which in
future might warrant utilising free antibiotic levels – and,
where TDM is not available, continuous infusion might
significantly improve AUIC.Abbreviations
AUIC: Area under the inhibitory curve; LZD: Linezolid; TDM: Therapeutic drug
monitoring; T > MIC: Time above the minimum inhibitory concentration.
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